24/7 Market News Snapshot 27 May, 2025 – Invivyd, Inc. Common Stock (NASDAQ:IVVD)

May 27, 2025

DENVER, Colo., 27 May, 2025 (www.247marketnews.com) – (NASDAQ:IVVD) are discussed in this article.
Invivyd, Inc. (IVVD) is experiencing notable market activity, with shares opening at $0.741 and currently trading at $0.941, reflecting a significant gain of over 25.72% from the previous close of $0.749. The company’s heightened trading volume of 5.09 million shares indicates strong investor interest, suggesting a bullish momentum that is capturing the attention of market analysts.

In a groundbreaking development, Invivyd has published vital outcomes from its CANOPY Phase 3 clinical trial of pemivibart, a long-acting monoclonal antibody, in the peer-reviewed journal Clinical Infectious Diseases. The publication highlights pemivibart’s commendable safety profile and efficacy in preventing symptomatic COVID-19, particularly in the context of emerging SARS-CoV-2 variants, including Omicron.

The CANOPY trial involved 788 adult participants and distinguished pemivibart as the sole authorized monoclonal antibody assessed with placebo-controlled effectiveness data amongst seropositive individuals facing current variants. The interim results demonstrated a striking 84% relative risk reduction in symptomatic COVID-19 compared to the placebo group throughout a six-month treatment window, providing hope for both immunocompromised and immunocompetent individuals.

The trial successfully met all primary and exploratory endpoints, positioning pemivibart as a potential pre-exposure prophylaxis (PrEP) for COVID-19. These findings hold significant implications for clinical practices and public health, especially amid the ongoing challenges posed by severe COVID-19 cases in vulnerable populations.

Marc Elia, Chairman of Invivyd, expressed enthusiasm regarding the publication, emphasizing the importance of educating healthcare professionals about the transformative capabilities of monoclonal antibodies in enhancing immunity among vaccinated individuals. Looking forward, Invivyd is committed to furthering its innovative portfolio, including efforts to advance the monoclonal antibody VYD2311 to address emerging viral threats effectively.

Related news for (IVVD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.